{"name":"Czech Lymphoma Study Group","slug":"czech-lymphoma-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNTkp3ZEFOT1FlcGd2MG91cmlrYVJhZGtkeHR3OUY2YVdDZHpIVDE4cFlPMTdYQ0ZYaFhxWjdfVFB1RE1xOUZCN0NYTVNnbGx2VG9QT3hjRldzNU5rRmNCZGIzSmNJWkVhR2NyVFJTSmZGM3B6UUpBZ1BOQTQxSDlWbEJfYVB1enUwSVFIN0hfU0Nwa0dk0gGUAUFVX3lxTE1OSndkQU5PUWVwZ3Ywb3VyaWthUmFka2R4dHc5RjZhV0NkekhUMThwWU8xN1hDRlhoWHFaN19UUHVETXE5RkI3Q1hNU2dsbHZUb1BPeGNGV3M1TmtGY0JkYjNKY0laRWFHY3JUUlNKZkYzcHpRSkFnUE5BNDFIOVZsQl9hUHV6dTBJUUg3SF9TQ3BrR2Q?oc=5","date":"2025-12-03","type":"pipeline","source":"Newswise","summary":"ASH 2025: Milder Chemo Works for Rare, Aggressive Lymphoma | Newswise - Newswise","headline":"ASH 2025: Milder Chemo Works for Rare, Aggressive Lymphoma | Newswise","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1KaV91R3pfZERUbUdYbUZsSm05c21POGlKbXpKNW9UV1ZUWFpORW5FSjM5d3JvSGZxMHBMTmJNcjhhQ29RRnViNWh0MFFabERJSEk4ZlAwQlplbHhJRC1Z?oc=5","date":"2021-09-22","type":"pipeline","source":"nature.com","summary":"Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma - nature.com","headline":"Super-enhancer-based identification of a BATF3/IL-2R−module reveals vulnerabilities in anaplastic large cell lymphoma","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}